BETABeta Drugs Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Risk gate: safety score is only 22/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Promoter holding: 0.0%
- • Dividend yield: 0.00%
- • Price vs SMA50: below
- • Supertrend: bearish
- • Double Top bearish signal (setup quality 61%)
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 25.3% YoY
- • Profit growth: 27.5% YoY
- • ROE: 16.9%
- • RSI: 52
Bear case
- • Promoter holding: 0.0%
- • Dividend yield: 0.00%
- • Price vs SMA50: below
- • Supertrend: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Promoter holding: 0.0%
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹136.02). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.